A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Active:	No
Cancer Type:	Breast Cancer	NCT ID:	NCT00781612
Trial Phases:	Phase II	Protocol IDs:	TDM4529g (primary) BO25430
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Genentech Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT00781612

Summary

This is a global, multicenter, open-label safety extension study. Participants receiving
single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination
with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are
active and receiving benefit at the closure of parent study are eligible for continued
treatment in this study.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.